Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to Hold at Jefferies Financial Group

Jefferies Financial Group cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report sent to investors on Wednesday, Briefing.com Automated Import reports. They currently have $23.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $46.00. Jefferies Financial Group also issued estimates for Supernus Pharmaceuticals’ Q4 2019 earnings at $0.56 EPS, FY2019 earnings at $2.04 EPS, FY2020 earnings at $1.18 EPS, FY2021 earnings at $1.18 EPS, FY2022 earnings at $1.67 EPS and FY2023 earnings at $0.06 EPS.

Other research analysts also recently issued research reports about the stock. BidaskClub upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday. TheStreet downgraded shares of Supernus Pharmaceuticals from a b- rating to a c+ rating in a report on Thursday, August 29th. Cowen set a $50.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, August 7th. Mizuho restated a buy rating on shares of Supernus Pharmaceuticals in a report on Wednesday, August 7th. Finally, ValuEngine upgraded shares of Supernus Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $46.50.

SUPN opened at $21.72 on Wednesday. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The company’s fifty day moving average price is $26.80 and its two-hundred day moving average price is $30.29. Supernus Pharmaceuticals has a 1-year low of $19.35 and a 1-year high of $49.25. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 10.60, a PEG ratio of 1.02 and a beta of 1.63.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.05). Supernus Pharmaceuticals had a return on equity of 21.80% and a net margin of 25.92%. The business had revenue of $102.14 million for the quarter, compared to analyst estimates of $108.70 million. During the same quarter in the previous year, the company posted $0.52 EPS. The business’s quarterly revenue was down .8% on a year-over-year basis. As a group, equities analysts forecast that Supernus Pharmaceuticals will post 2.14 earnings per share for the current fiscal year.

In other news, CEO Jack A. Khattar bought 7,200 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, August 23rd. The stock was purchased at an average price of $26.39 per share, for a total transaction of $190,008.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 6.57% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Boston Advisors LLC grew its stake in shares of Supernus Pharmaceuticals by 52.6% in the 3rd quarter. Boston Advisors LLC now owns 69,935 shares of the specialty pharmaceutical company’s stock worth $1,922,000 after acquiring an additional 24,112 shares in the last quarter. First Mercantile Trust Co. grew its stake in shares of Supernus Pharmaceuticals by 31.5% in the 3rd quarter. First Mercantile Trust Co. now owns 2,173 shares of the specialty pharmaceutical company’s stock worth $60,000 after acquiring an additional 520 shares in the last quarter. Malaga Cove Capital LLC grew its stake in shares of Supernus Pharmaceuticals by 43.1% in the 3rd quarter. Malaga Cove Capital LLC now owns 14,564 shares of the specialty pharmaceutical company’s stock worth $400,000 after acquiring an additional 4,384 shares in the last quarter. Renaissance Group LLC grew its stake in shares of Supernus Pharmaceuticals by 3.8% in the 3rd quarter. Renaissance Group LLC now owns 10,496 shares of the specialty pharmaceutical company’s stock worth $288,000 after acquiring an additional 380 shares in the last quarter. Finally, California Public Employees Retirement System grew its stake in shares of Supernus Pharmaceuticals by 37.0% in the 3rd quarter. California Public Employees Retirement System now owns 103,473 shares of the specialty pharmaceutical company’s stock worth $2,843,000 after acquiring an additional 27,961 shares in the last quarter. Hedge funds and other institutional investors own 99.14% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Further Reading: Average Daily Trade Volume – ADTV

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.